Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood

• US 5,004,681 A
• Filed: 11/12/1987
• Issued: 04/02/1991
• Est. Priority Date: 11/12/1987
• Status: Expired due to Term

• Current Assignee: Pharmastem Therapeutics Incorporated
• Original Assignee: Biocyte Corporation
• Inventors: Boyse, Edward A., Broxmeyer, Hal E., Douglas, Gordon W.
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US07/119,746
• Time in Patent Office: 1,237 Days
• Field of Search: 435/2, 424/101
• US Class Current: 435/2
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 35/54 Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 2502/11 blood or immune system cells
• CPC Class Codes: C12N 2502/30 tumour cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: Y10S 435/948 using viruses or cell lines

Abstract

The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.

Claims

1. A composition comprising:

(a) a plurality of viable human neonatal or fetal hematopoietic stem cells derived from the blood; and

(b) cryopreservative.

2. A composition of claim 1 which further comprises a viable human neonatal or fetal hematopoietic progenitor cells.

3. A composition of claim 1 which further comprises whole neonatal or fetal blood.

4. A composition of claim 1 which further comprises an anticoagulent.

5. The composition of claim 1, 2, 3 or 4 in which the cryopreservative comprises dimethyl sulfoxide.

6. A composition of claim 1 in which the hematopoietic stem cell is characterized by the ability to produce a progeny cell which can produce a colony of granulocyte, erythroid, monocyte, or macrophage progeny in vitro.

7. The composition of claim 2 in which the progenitor cell is characterized by the ability to produce a colony of granulocyte, erythroid, monocyte, or macrophage progeny in vitro.

8. The composition of claim 1 in which the hematopoietic stem cell is characterized by the abiliyt to seed to a spleen and produce a colony of progeny cells, upon introduction into a mammal.

9. The composition of claim 1 in which the hematopoietic stem cell is characterized by the ability to reconstitute the hematopoietic system of a host into which it is introduced.